258 related articles for article (PubMed ID: 18449940)
21. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
22. Strategies for ovarian cancer prevention.
Dann RB; Kelley JL; Zorn KK
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):667-86, viii. PubMed ID: 18061863
[TBL] [Abstract][Full Text] [Related]
23. [Possibilities of examination of familial breast cancers and ovarian cancers. Use of molecular-genetic analysis of the BRCA1 gene and the BRCA2 gene].
Backe J; Mulfinger L
Krankenpfl J; 1996 Oct; 34(10):440-5. PubMed ID: 8949022
[No Abstract] [Full Text] [Related]
24. High risk men's perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer.
Quinn GP; Vadaparampil ST; Miree CA; Lee JH; Zhao X; Friedman S; Yi S; Mayer J
Hum Reprod; 2010 Oct; 25(10):2543-50. PubMed ID: 20713415
[TBL] [Abstract][Full Text] [Related]
25. Pretest genetic counseling informs patients with BRCA mutation.
Printz C
Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
[No Abstract] [Full Text] [Related]
26. DNA testing. Genetic screen misses mutations in women at high risk of breast cancer.
Stokstad E
Science; 2006 Mar; 311(5769):1847. PubMed ID: 16574828
[No Abstract] [Full Text] [Related]
27. Psychological distress and quality of life associated with genetic testing for breast cancer risk.
Smith AW; Dougall AL; Posluszny DM; Somers TJ; Rubinstein WS; Baum A
Psychooncology; 2008 Aug; 17(8):767-73. PubMed ID: 17992698
[TBL] [Abstract][Full Text] [Related]
28. Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations.
Silva E; Lynch H
Breast J; 2006; 12(3):280-1; author reply 282-4. PubMed ID: 16684334
[No Abstract] [Full Text] [Related]
29. One risk fits all?
De Bock GH; Mourits MJ; Oosterwijk JC
J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
[No Abstract] [Full Text] [Related]
30. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
31. Penetrance of BRCA1/BRCA2 specific gene mutations in Iranian women with breast cancer.
Hashemian AH; Hajizadeh E; Kazemnejad A; Atri M; Mehdipour P
Saudi Med J; 2009 Jan; 30(1):41-4. PubMed ID: 19139771
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
33. The genetics of ovarian cancer: concepts in testing and counseling.
Hartenbach EM; Schink JC
Curr Opin Obstet Gynecol; 1996 Oct; 8(5):339-42. PubMed ID: 8941429
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?
Leunen K; Drijkoningen M; Neven P; Christiaens MR; Van Ongeval C; Legius E; Amant F; Berteloot P; Vergote I
Breast Cancer Res Treat; 2008 Jan; 107(1):79-86. PubMed ID: 17431765
[TBL] [Abstract][Full Text] [Related]
35. Test results for breast cancer mutation questioned.
Health News; 2006 May; 12(5):2. PubMed ID: 16685747
[No Abstract] [Full Text] [Related]
36. Socioeconomic influences on the effects of a genetic testing direct-to-consumer marketing campaign.
Bowen DJ; Harris J; Jorgensen CM; Myers MF; Kuniyuki A
Public Health Genomics; 2010; 13(3):131-42. PubMed ID: 19641293
[TBL] [Abstract][Full Text] [Related]
37. BRCA1: genetic testing and hereditary breast and ovarian cancer.
Ross DW
Arch Pathol Lab Med; 1997 Jul; 121(7):754-5. PubMed ID: 9240915
[No Abstract] [Full Text] [Related]
38. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort.
Fortuny D; Balmaña J; Graña B; Torres A; Ramón y Cajal T; Darder E; Gadea N; Velasco A; López C; Sanz J; Alonso C; Brunet J
Hum Reprod; 2009 Apr; 24(4):1000-6. PubMed ID: 19112076
[TBL] [Abstract][Full Text] [Related]
39. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
40. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
